Erlotinib

Overview

Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1 , with an IC 50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2 , GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer , gastric cancer , papillary renal cell carcinoma, pancreatic cancer , renal fibrosis, and other conditions.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Renal Disease | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Lung Adenocarcinoma | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ERK | Products > Signaling Pathways > GSK-3 | Products > Signaling Pathways > β-catenin | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > OAT

Product Information

• Catalog No.: HY-50896
• CAS No.: 183321-74-6
• Molecular Formula: C22H23N3O4
• Molecular Weight: 393.44
• Purity: 99.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1.25 mg/mL (3.18 mM); Clear solution
• Availability: In-stock

Source

Original product source